Onvatilimab
Based on 1 publication(s) in Google Scholar
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research.
For research use only. We do not sell to patients.
- Purity : 98.00%
- CAS No.: 1969313-51-6
- Molecular Weight:144.52 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Onvatilimab
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
B7-H5/VISTA
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded VISTA/B7-H5 Protein, Human (HEK293, Fc, HY-P77879) on SA biosensor, can bind Onvatilimab with an affinity constant of 2.039E-10 M as determined in BLI assay. -
Flow cytometric analysis of 106 Jurkat cells labeling Onvatilimab (HY-P99040, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1969313-51-6
-
Appearance Liquid
-
Molecular Weight 144.52 kDa
-
Color Colorless to light yellow
-
SMILES
[Onvatilimab]
-
Synonyms
JNJ-61610588; CI-8993; VSTB112
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
IGSF11-VISTA is a critical and targetable immune checkpoint axis in diffuse midline glioma. [Abstract]2026 Jan 22:S1535-6108(25)00554-9. PMID: 41576930
Purity & Documentation
-
Data Sheet (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Katsiaryna Marhelava, et al. Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer. Cancers (Basel). 2019 Nov 8;11(11):1756. [Content Brief]
[2]. Wu L, et al. METTL3-VISTA axis-based combination immunotherapy for APC truncation colorectal cancer. J Immunother Cancer. 2024 Dec 9;12(12):e009865. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)